RhoVac recruits Steffen Wad Jørgensen as Chief Development Officer
Dec 04, 2019
RhoVac AB ("RhoVac") announces today, December 4th 2019, that Steffen Wad Jørgensen is appointed Chief Development Officer as of January 1, 2020. In light of Anders Ljungqvist's coming retirement in 2020, Steffen Wad Jørgensen will gradually assume the overall responsibility for the further development of the RV001 project.
RhoVac announces that Steffen Wad Jørgensen is appointed Chief Development Officer as of January 1, 2020. He will gradually assume the overall responsibility for the development project RV001 from Anders Ljungqvist, who will retire later in 2020. However, also after retirement form his operational assignment, Anders Ljungqvist aims to continue on RhoVac's board and as an advisor to the company.
Steffen Wad Jørgensen comes to RhoVac with a long and solid background as a drug developer. Steffen holds a pharmacy degree, and he also holds a PhD in Immunology and Clinical Chemistry. His broad experience includes both formulation development and analysis as well as project coordination of both early and late stage development phases. Most pertinent for the assignment at RhoVac is that Steffen, over the course of his long tenure with Lundbeck, has been promoted to increasingly senior positions within project management in research & development, and that he has also gained many years of experience in both early and late development phases, which is essential for the development of the RV001 project.
Comment from Anders Ljungqvist, COO: “I am glad that we have found the right person to take over operationally when I intend to retire during the course of 2020. I feel confident that Steffen will lead the RV001 project all the way to the finishing line in the best possible way. As one of RhoVac's largest shareholders, I intend to continue my work on the Board with full force. "
Comment from Anders Månsson, CEO: “As Anders Ljungqvist expressed his wish to retire from his operational assignment during the course of 2020, I am very pleased that we have found a good replacement in Steffen. The fact that Steffen starts as early as January means that he and Anders Ljungqvist will have all the time needed to hand over development responsibility in the best possible way ensuring continued project progress and giving Steffen a flying start. The fact that Steffen also he also has solid experience in supporting business development from his time at Lundbeck, I see as a pivotal advantage."